#1 Clinical Trials Search in Europe

Study on the Effectiveness and Safety of Ademetionine Injections for Patients with Major Depressive Disorder Not Responding to Antidepressants

3 1 1

What is this study about?

This clinical trial is focused on studying the effectiveness and safety of a treatment called Samyr for individuals with Major Depression Disorder. Major Depression Disorder is a mental health condition characterized by persistent feelings of sadness and loss of interest in activities. The treatment being tested, Samyr, is administered as an injection and contains the active substance ademetionine. The study aims to determine if Samyr can enhance the effects of existing antidepressant medications in patients who have not experienced sufficient improvement in their symptoms.

Participants in the study will receive either the Samyr injection or a placebo injection, which is a substance with no active medication. The study is designed to compare the outcomes of these two groups to see if Samyr provides additional benefits. The trial will take place over a period of time, during which participants will continue their regular antidepressant tablet treatment. The main goal is to observe changes in the severity of depression symptoms after 7 days of treatment, using a scale known as the Montgomery-Asberg Depression Rating Scale (MADRS).

Throughout the study, participants will attend scheduled visits where their progress will be monitored. The researchers will assess changes in depression symptoms and overall well-being using various measures, including the HRDS-6 and other scales. The study is conducted in a way that ensures neither the participants nor the researchers know who is receiving the actual medication or the placebo, which helps maintain the study’s objectivity. The results will help determine if Samyr is a beneficial addition to current antidepressant treatments for those with Major Depression Disorder.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying the diagnosis of major depression disorder and ensuring the current antidepressant treatment is stable.

The Montgomery-Asberg Depression Rating Scale (MADRS) score is evaluated to establish a baseline.

2 randomization

Participants are randomly assigned to receive either Samyr or a placebo. This process is double-blind, meaning neither the participant nor the study team knows which treatment is being administered.

3 treatment administration

The treatment involves intramuscular injections of either Samyr (400 mg/5ml) or a placebo (saline solution).

Injections are administered according to the study schedule, which is designed to enhance the current antidepressant treatment.

4 monitoring and assessments

Regular visits are scheduled to monitor progress and assess the effectiveness of the treatment.

The primary focus is on changes in the MADRS score after 7 days of treatment, with additional assessments at scheduled visits.

5 completion of study

The study concludes with a final assessment to evaluate the overall change in depression symptoms.

Participants’ experiences and outcomes are documented for analysis.

Who Can Join the Study?

  • The patient must provide written and signed informed consent before starting any study-related procedures.
  • The patient must be between 18 and 65 years old, including both ages.
  • The patient must be able and willing to follow the study’s requirements, including attending visits and completing assessments.
  • The patient must have a primary diagnosis of Major Depression Disorder (MDD) for at least 12 weeks, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), which is a guide used by healthcare professionals to diagnose mental disorders.
  • The patient must be taking a prescribed SSRI (such as citalopram, escitalopram, sertraline, or paroxetine) or SNRI (such as venlafaxine or duloxetine) antidepressant at an approved and stable dose for at least 4 weeks before the screening. SSRI and SNRI are types of medications used to treat depression.
  • The patient must have shown a partial response to the prescribed antidepressant in the last 8 weeks before screening. A partial response means less than 50% reduction in symptoms, based on the doctor’s judgment and treatment history.
  • The patient must have a Montgomery-Asberg Depression Rating Scale (MADRS) score of at least 22 at screening and less than 15% reduction at baseline after initial treatment. Additionally, the patient must have a MADRS score of 19 or higher at the time of randomization. The MADRS is a tool used to measure the severity of depression symptoms.

Who Cannot Join the Study?

  • Patients who have a different condition than Major Depression Disorders cannot participate.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are part of a vulnerable population, meaning they might need special protection or care, cannot participate.
  • Patients who are not eligible based on other specific criteria set by the study cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Azienda Ospedaliera di Padova Padua Italy
Universita’ Di Pisa Pisa Italy
Dothrwhhrxga Sscnlu Mcxwbmt ckd Ppkiwkfod Scq dpzuq Swtqpksdg Giulianova Italy

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Italy Italy
Recruiting
17.01.2019

Trial locations

Investigated drugs:

Samyr IM is being tested in this clinical trial as an additional treatment to help improve the effects of antidepressants in patients with major depression disorder. The goal is to see if adding Samyr IM can enhance the overall treatment and lead to better improvement in depression symptoms for those who haven’t had enough relief from their current antidepressant medications.

Major Depressive Disorder – This is a mental health condition characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in activities. It can affect how a person thinks, feels, and handles daily activities, such as sleeping, eating, or working. The disorder often involves changes in sleep patterns, appetite, energy level, concentration, daily behavior, or self-esteem. Symptoms must be present for at least two weeks for a diagnosis. The condition can vary in severity and may occur as a single episode or recur over time. It is a common disorder that can significantly impact a person’s quality of life.

Trial ID:
2024-513022-29-00
Protocol code:
MYL-1603N-3002
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutated non‑small cell lung cancer after chemoradiotherapy

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Greece Italy The Netherlands Poland

  • Venetoclax added to drug combination improves survival in children with relapsed acute myeloid leukemia

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +8